Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

5.615 +0.295 (+5.55%)
Streaming Delayed Price Updated: 2:26 PM EDT, May 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biocryst Pharma Inc

< Previous 1 2 3 4 5 6 Next >
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally. 
Via The Motley Fool
BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic... 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024
BCRX stock results show that BioCryst Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
A Preview Of BioCryst Pharma's Earnings
Via Benzinga
What's Going On With BioCryst Pharmaceuticals Stock?
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares are trading higher Monday. 
Via Benzinga
Where BioCryst Pharma Stands With Analysts
Via Benzinga
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
These penny stocks offer triple digit returns to investors right now but not many investors are aware of them. 
Via InvestorPlace
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
What's Going On With BioCryst Stock After Earnings?
BioCryst reported quarterly losses of 28 cents per share, missing the analyst consensus estimate of losses of 24 cents by 16.67% and representing a 26.32% increase over losses of 38 cents per share... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
What 7 Analyst Ratings Have To Say About BioCryst Pharma
Via Benzinga
Analyst Expectations for BioCryst Pharma's Future
Via Benzinga
Why BioCryst Pharmaceuticals Stock Is Soaring Today
The biotech's Q1 earnings report contained a number of positives. 
Via The Motley Fool
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
BioCryst Clocks 37.8% Revenue Growth In Q1 On Solid New Patient Growth
Via Benzinga
Recap: BioCryst Pharma Q1 Earnings
Via Benzinga
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results. 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
Via Benzinga
3 Magnificent Growth Stocks to Buy on the Dip
These three biotech stocks are attractive buys right now. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2023
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q2 2023 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2023
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Why Is BioCryst Pharmaceuticals (BCRX) Stock Down 8% Today?
BioCryst Pharmaceuticals (BCRX) stock is slipping on Tuesday after the biotech company announced new funding to pay down debts. 
Via InvestorPlace
Ericsson, Johnson & Johnson, Goldman Sachs And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.